Lutetium (lu177) lilotomab satetraxetan is under clinical development by Nordic Nanovector and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lutetium (lu177) lilotomab satetraxetan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium (lu177) lilotomab satetraxetan overview
Betalutin (177Lu-HH1) is under development for the treatment of non-Hodgkin B-cell lymphoma of subtypes follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell lymphoma and other non-hodkin's lymphomas in combination with CD20. It is administered as an intravenous and parenteral route. The drug candidate is a monoclonal antibody (HH1) conjugated with a radionuclide Lutetium-177 (177Lu). It is a radioimmunotherapeutic developed using nanovector targeting technology. Betalutin targets CD37 antigen.
It was under development for the treatment of diffuse large B-cell lymphoma.
Nordic Nanovector overview
Nordic Nanovector, formerly Nordic Nanovector is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumor-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programs and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway
For a complete picture of Lutetium (lu177) lilotomab satetraxetan’s drug-specific PTSR and LoA scores, buy the report here.